FLT3 and acute myeloid leukemia: Despite treatments such as maximally intensive chemotherapies and allogeneic stem cell transplantation, survival rates have remained mostly unchanged for AML patients until recent years when there has been a significant shift towards the use of novel and effective, targeted therapies including inhibitors of mutant FMS-like tyrosine kinase 3 (FLT3) [6] and isocitrate dehydrogenase (IDH), the B cell lymphoma 2 inhibitor venetoclax and the hedgehog pathway inhibitor glasdegib (reviewed in [7]).